ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

AVBP Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI remains negative

Q1 FY2026 Accumulated OCI was -$270K, compared with -$17K a year earlier.

Context

  • Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -1488.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$270K-2028.6% QoQ
Last fiscal yearDec 2025
$14K+106.6% YoY
Year agoMar 2025
-$17K-1488.2% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1488.2%——
1 year+106.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
14K USD
Year-over-year change
+106.6%

Accumulated OCI vs competitors

How AVBP compares with its peers on the latest reported figures

  • AVBP's Mar 2026 Accumulated OCI of -$270K is the 5th highest of the 11 companies compared; the peer median is -$392K.
  • Its year-over-year change of -1488.2% is the lowest of 11, against a peer median of -156.5%.
  • Accumulated OCI amounts to 0.1% of total assets for AVBP, versus a peer median of 0.1%.
AVBP Competitors Peer median
Accumulated OCI for AVBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZLABZai Lab LimitedJun 2026$214K -99.5%+5.0%0.0%
TYRATyra Biosciences, Inc.Mar 2026$107K -84.4%—0.0%
PBYIPuma Biotechnology, Inc.Mar 2026-$31K -181.8%+540887.8%0.0%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026-$36K -89.5%—0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026-$270K -1488.2%—0.1%
ORICORIC Pharmaceuticals, Inc.Mar 2026-$290K -238.8%—0.1%
IDYAIDEAYA Biosciences, Inc.Mar 2026-$494K -131.2%—0.0%
EXELExelixis, Inc.Jul 2026-$2.01M -249.2%—0.1%
NUVBNuvation Bio Inc.Jun 2026-$2.61M -698.5%—0.4%
ERASErasca, Inc.Sep 2026-$4.19M -744.8%—0.4%
HCMHUTCHMED (China) LimitedDec 2025-$4.53M +60.9%—0.3%
Peer median (excluding AVBP) -$392K-156.5%+270446.4%0.1%

Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents37.28M163.37M150.39M74.29M45.54M
Short-term Investments000144.57M267.28M
Net Receivables000500K60K
Inventory00000
Other Current Assets5.64M18.92M9.21M7.21M20.02M
Total Current Assets42.95M182.62M159.97M226.98M332.9M
Property, Plant & Equipment (Net)0139K291K154K13K
Goodwill00000
Intangible Assets00000
Long-term Investments00047.68M0
Tax Assets00000
Other Non-current Assets87K72K2.84M126K259K
Total Non-current Assets87K211K3.13M47.96M272K
Total Assets43.04M182.83M163.1M274.94M333.17M
Account Payables293K3.09M4.53M3.78M5.93M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0004.16M6.55M
Total Current Liabilities1.82M8.36M11.62M17.27M25.95M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities011K177K14K0
Total Liabilities1.82M8.37M11.8M17.29M25.95M
Common Stock0003K4K
Retained Earnings(51.61M)(88.51M)(157.85M)(238.33M)(404.64M)
Accumulated OCI(2K)00(211K)14K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity41.22M174.46M151.3M257.65M307.22M
Total Debt0139K317K176K14K
Net Debt(37.28M)(163.23M)(150.07M)(74.12M)(45.53M)

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.